DUPIXENT reduced SCS use in children aged 6-11 years2

~50% of children aged 6-12 years were reported to receive SCS bursts for asthma in the previous 3 months in an observational study (n=770)5,f
VOYAGE
59%

reduction in SCS courses in children with EOS ≥150 cells/μL or FeNO
≥20 ppb through Year 1 with DUPIXENT 100 mg/200 mg Q2W + SOC (n=236) vs placebo + SOC (n=114) (adjusted annualized total SCS courses in all patients: 0.35 [95% CI: 0.26, 0.48] vs 0.86 [95% CI: 0.62, 1.20]) (secondary endpoint)1,2

66%

reduction in SCS courses in children with EOS ≥300 cells/μL through
Year 1 with DUPIXENT 100 mg/200 mg Q2W + SOC (n=175) vs placebo + SOC (n=84) (adjusted annualized total SCS courses in all patients: 0.27 [95% CI: 0.19, 0.40] vs 0.81 [95% CI: 0.56, 1.15]) (secondary endpoint)1,2

EXCURSION OLE (post hoc analysis)
ZERO

RESCUE SCS USE in 81% of children aged 6-11 years
through Year 2 who had 1 severe prior exacerbation
(DUPIXENT/DUPIXENT, n=77)6

Zero rescue SCS use through Year 26:

  • In 70% of children aged 6-11 years who had 1 severe prior exacerbation (placebo/​DUPIXENT, n=43)
  • In 66% of children 6-11 years who had ≥2 severe prior exacerbations (DUPIXENT/​DUPIXENT, n=132)
  • In 54% of children aged 6-11 years who had ≥2 severe prior exacerbations (placebo/​DUPIXENT, n=63)

EXCURSION OLE results are descriptive. Definitive conclusions cannot be made as this was a post hoc analysis of open-label extension data.

Data were not multiplicity controlled, and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of nonresponders.

fTENOR was a 3-year, multicenter, observational study of 4756 patients with severe or difficult-to-treat asthma, including 770 children aged 6-12.5

EOS, eosinophil; FeNO, fractional exhaled nitric oxide; OLE, open-label extension; Q2W, once every 2 weeks; QoL, quality of life; SCS, systemic corticosteroid; SOC, standard of care.